A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers.

Trial Profile

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2016

At a glance

  • Drugs Amatuximab (Primary)
  • Indications Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov (NCT01521325).
    • 09 Jan 2013 Planned End Date changed from 1 Jan 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov. (NCT01521325)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top